COVID-19 pandemic caused by SARS-CoV-2, a new type of coronavirus that causes severe acute respiratory syndrome in humans, has caused great concern to humanity and significantly affected life all over the world. SARS-CoV-2 has been transmitted to millions of people due to the lack of established treatments and vaccines. Vaccination applications in the world are regarded as both the most effective and the most economical and promising method in the protection and control of infectious diseases in humans and animals. The determination of the genome and protein structure of SARS-CoV-2 in a record-breaking time allowed the development of prophylactic virus-like particle, subunit, RNA, DNA and vector vaccines as well as inactivated or attenuated viral vaccines. In addition, the experiences obtained from SARSCoV, MERS-CoV which are closely related to this virus, and animal coronavirus infections, have previously caused epidemics in humans, and contributed greatly to this process. The latest coronavirus pandemic has caused universities and research institutes around the world to change their work plans. These institutions have entered into a busy schedule to determine how the disease can be stopped with a specific vaccine. Currently, many companies, universities and institutes around the world and in our country have included an effective vaccine development program against SARS-CoV-2. In this review, previous experiences with coronavirus vaccines and current approaches to SARS-CoV-2 vaccine development, methods and strategies carried out around the world and vaccine candidates are reviewed.